References

1. Pfizer Data on File (DOF). DRAFT Prevenar 13 Global Summary of Product Characteristics (SmPC).

2. Pfizer Data on File (DOF). Bryant K., Frenck, R., et al. ECCMID Draft Abstract. ePoster 736. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults aged 18–49 years, naïve to 23-valent pneumococcal polysaccharide vaccine. April 28, 2013.

3. Centers for Disease Control and Prevention (CDC). Pneumococcal Disease. CDC Pink Book. 2011;16:233-248.

4. World Health Organization (WHO). 23-valent pneumococcal polysaccharide vaccine. WHO Position Paper. Wkly Epidemiol Rec. 2008;83(42):373-384.

5. World Health Organization (WHO). Immunization, Vaccines and Biologicals. Pneumoccocal Vaccines. April 2003. Wkly Epidemiol Rec. 2003;78(14):97-120.

6. Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 1997;46(RR-8):1-24.

7. Prevnar 13 Prescribing Information. http://labeling.pfizer.com/showlabeling.aspx?id=501.

Copyright Business Wire 2010

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux